department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

LACOSAMIDE · pharmadog

pharmadog
drugs
LACOSAMIDE

drug

patient view →

LACOSAMIDE

Marketedupdated 2mo ago

by UCB SA

Approved

community read0 votes

all catalysts(6)

approval · 6

LACOSAMIDE — FDA approval

LACOSAMIDE — FDA approval

LACOSAMIDE — FDA approval

LACOSAMIDE — FDA approval

LACOSAMIDE — FDA approval

LACOSAMIDE — FDA approval

News(0)

no news has mentioned this drug yet

brand

LACOSAMIDE

generic

LACOSAMIDE

indication

Generalized Seizures

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Jun 5, 2040

~13.9 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (9)

Jun 5, 2040formulationUS 11337943
Jun 5, 2040formulationUS 11337943
Jun 5, 2040formulationUS 11337943
Jun 5, 2040formulationUS 11883374
Jun 5, 2040formulationUS 11883374
Jun 5, 2040formulationUS 11883374
Jun 5, 2040formulationUS 12042474
Jun 5, 2040formulationUS 12042474
Jun 5, 2040formulationUS 12042474

FDA exclusivities (6)

Apr 28, 2026D-188New Indication (3y)
Apr 28, 2026D-188New Indication (3y)
Apr 28, 2026D-188New Indication (3y)
Apr 28, 2026D-188New Indication (3y)
Apr 28, 2026D-188New Indication (3y)
Apr 28, 2026D-188New Indication (3y)

Data sources

openFDA · ClinicalTrials.gov

last refreshed 56m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 7

tagApproval16 co-mentions · 8 sources
druglacosamide ER13 co-mentions · 13 sources
companyGlenmark Pharmaceuticals Ltd12 co-mentions · 4 sources
tagSmall Molecule8 co-mentions · 8 sources
companyHetero Labs Ltd6 co-mentions · 6 sources
tagRecall6 co-mentions · 5 sources
companyApotex Corp2 co-mentions · 1 sources

Trials studying LACOSAMIDE

phase3Evaluation of the Efficacy, Safety, and Tolerability of Lacosamide in Major Depressive Episodes of Bipolar Disorder Types I and II.recruitingn=40
phase2A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizuresterminatedn=29
phase3A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatmentcompletedn=48
phase2A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Pilot Trial to Assess the Efficacy, Safety, and Tolerability of SPM 927 in Subjects With Postherpetic Neuralgia (PHN).completedn=44
phase2An Open-label follow-on Trial to Assess the Long-term Safety and Efficacy of Oral SPM 927 in Subjects With Diabetic Neuropathycompletedn=69
phase3Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizurescompletedn=239
phase3Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.completedn=621
phase3A Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Diabetic Neuropathycompletedn=371

more trials →